TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06218199
Drug: Torsemide
Normalized name: Torsemide
DrugBank: Torasemide (DB00214)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration
Study: NCT06218199
Drug: sacubitril/valsartan
Normalized name: SACUBITRIL/VALSARTAN
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral administration
Study: NCT06218199
Drug: Hydralazine
Normalized name: Hydralazine
DrugBank: Hydralazine (DB01275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration
Study: NCT06218199
Drug: Isosorbide Dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration
Study: NCT05845489
Drug: Clopidogrel treatment group
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients assigned to the clopidogrel treatment group will maintain clopidogrel 75mg once a day for at least 5 years.
Study: NCT05229991
Drug: Lonafarnib
Normalized name: LONAFARNIB
DrugBank: Lonafarnib (DB06448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: once-daily dosing of lonafarnib 50 mg with ritonavir 200 mg over a 48-week treatment period.
Study: NCT05229991
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: once-daily dosing of lonafarnib 50 mg with ritonavir 200 mg over a 48-week treatment period.
Study: NCT03244072
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracameral injection
Study: NCT05333406
Drug: EN001
Normalized name: ReN001
DrugBank: ReN001 (DB05236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows.~Dose group A (Low dose): 5.0x10\^5 cells/kg
Study: NCT05333406
Drug: EN001
Normalized name: ReN001
DrugBank: ReN001 (DB05236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows.~Dose group B (High dose): 2.5x10\^6 cells/kg
Study: NCT05654896
Drug: Ceftriaxone Sodium
Normalized name: Ceftriaxone Sodium
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic will be administered prophylactically for TACE
Study: NCT04565171
Drug: Yimitasvir Phosphate Capsule
Normalized name: fludarabine phosphate Oral Capsule
DrugBank: Yimitasvir (DB18768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAG181 100 mg (100 mg Capsule) administered orally
Study: NCT04371627
Drug: Viaskin Peanut
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily epicutaneous delivery
Study: NCT05849779
Drug: Inhaled sedation with sevoflurane
Normalized name: sevoflurane Inhalation Solution
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In both arms, the management of sedation will be conducted in the broader picture of ICU patient care, as per current standard practice in participating ICUs, and following the current guidelines for Pain, Agitation, Delirium, Immobility, and Sleep Disruption (PADIS) published in 2018 by the Society of Critical Care Medicine.~Among many recommendations, this will include the monitoring and titration of both sedation and analgesia using validated scores such as the Richmond Agitation-Sedation Scale (RASS) for sedation. As a result of the current recommendations, the level, dose, and duration of sedation will vary among patients and will be decided by the treating clinicians. The choice of the analgesic drug(s) will be as per the treating clinicians.~Other aspects of critical care will adhere to standard care, including the use of the Checklist for Lung Injury Prevention (CLIP).
Study: NCT06072534
Drug: Mivacurium Chloride
Normalized name: Mivacurium Chloride
DrugBank: Mivacurium (DB01226)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: emergence modified sequence intubation
Study: NCT04604652
Drug: HTD1801 (BUDCA)
Normalized name: TUDCA
DrugBank: Tauroursodeoxycholic acid (DB08834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTD1801 (BUDCA) 250 mg tablets. Dose 1000 mg twice daily with food for 12 weeks.
Study: NCT06510413
Drug: Loxoprofen Sodium Patches(reference product)
Normalized name: loxoprofen
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose of one patch in each period; Apply for 24 hours each time
Study: NCT06510413
Drug: Loxoprofen Sodium Patches(test product )
Normalized name: loxoprofen
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose of one patch in each period; Apply for 24 hours each time
Study: NCT04685499
Drug: OBP-301
Normalized name: DNA (recombinant human telomerase-specific replication-competent oncolytic adenovirus 5 vector OBP-301)
DrugBank: Tipapkinogene sovacivec (DB06239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telomerase-specific Type 5 Adenovirus. OBP-301 OBP 301 will be injected intratumorally into tumor lesions.
Study: NCT04685499
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard dose pembrolizumab 200 mg IV every 3 weeks for up to one year
Study: NCT05347979
Drug: Dabigatran Etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran will be administered orally as a 75 mg capsule on Day 1 and Day 12.
Study: NCT05347979
Drug: Relacorilant
Normalized name: Relacorilant
DrugBank: Relacorilant (DB14976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relacorilant will be administered orally as 4 X 100 mg capsules (400 mg) on Days 3 through 13.
Study: NCT05239312
Drug: Antimicrobial
Normalized name: ANTIMICROBIALS
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implementation of antimicrobial protocol for empirical treatment which will be done according to the results of antibiotic susceptibility
Study: NCT05001360
Drug: XBI-302 + Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After gut preparation, a single dose of FMT will be performed via oral administration. Subsequently, nine combined treatment cycles that composed of anti-PD-1 infusions (Nivolumab at 240 mg, q2w) and additional FMT capsules, and 3 single treatment cycles of anti-PD-1 infusions will be administered.
Study: NCT06313801
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 50 mg/m2 intravenously on day 1
Study: NCT06313801
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 85 mg/m2 on Day 1
Study: NCT06313801
Drug: Calcium folinate
Normalized name: Calcium folinate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m2 2-hour intravenous infusion on day 1
Study: NCT05655754
Drug: Methohexital
Normalized name: Methohexital
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: anesthesia during ECT
Study: NCT05655754
Drug: Ketofol
Normalized name: Ketozole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: anesthesia during ECT
Study: NCT05972044
Drug: Solriamfetol 150 mg
Normalized name: solriamfetol 150 MG
DrugBank: Solriamfetol (DB14754)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Solriamfetol tablets, taken once daily
Study: NCT05972044
Drug: Solriamfetol 300 mg
DrugBank: Solriamfetol (DB14754)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Solriamfetol tablets, taken once daily
Study: NCT06041984
Drug: Glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of glycopyrrolate 0.2mg
Study: NCT04999878
Drug: Ruxolitinib, Etoposide, Dexamethasone, Gemcitabine, Pegaspargase, cis-platinum
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All enrolled patients will receive a regimen containing Ruxilitinib, Etoposide, Dexamethasone, Gemcitabine, Pasparase and Platinum for 28 days. The specific medication is as follows:~Ruxilitinib 10 mg, bid, d1-28, P.O. Etoposide 100mg per week, two weeks, ivgtt Dexamethasone, 15mg/(m²·d)，d1-12，10 mg/ (m²·d) ，d13-14，5 mg/ (m²·d) ，d15-21，2.5mg/(m²·d)，d22-28，ivgtt or P.O.~Gemcitabine, 0.5 g/m², d8, ivgtt Pegaspargase, 2500IU/m², d9, im Platinum, 20mg/m² d10 d11, ivgtt After the treatment, patients will be given disease specific chemotherapy regimen to treat lymphoma according to patient's different lymphoma subtype.
Study: NCT06411223
Drug: Cabotegravir/Rilpivirine
Normalized name: CABOTEGRAVIR/RILPIVIRINE
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Long-acting injectable treatment prescribed to treat HIV-1 infection in people 12 years and older and who weigh at least 77 lbs (35kg), to replace their current HIV-1 medicines when their healthcare provider determines they meet certain requirements.
Study: NCT05795101
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: via IV, protocol determined dosage once per cycle up to eight cycles. Each cycle will last for 21 days (three weeks).
Study: NCT05795101
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: via IV, protocol determined dosage once per cycle up to eight cycles. Each cycle will last for 21 days (three weeks).
Study: NCT05918107
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV infusion
Study: NCT05918107
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT05918107
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT05836948
Drug: SHR-9839
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly fixed dose injection of SHR-9839
Study: NCT05576480
Drug: Penpulimab
Normalized name: Penpulimab
DrugBank: Penpulimab (DB16747)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply once in the first week, then every 3 weeks from the third week for four cycles
Study: NCT06185933
Drug: Lidocaine Spray
Normalized name: lidocaine Mucosal Spray
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharyngeal anesthesia using a topical lidocaine spray was administered in the preprocedure room, in the absence of the endoscopist or the research assistant. 5 minute before the UGE without any sedation
Study: NCT06185933
Drug: Lidocaine Viscous+Lidocane spray
Normalized name: lidocaine Medicated Patch [Lidocan]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharyngeal anesthesia using topical viscous lidocaine solution + lidocaine spray were administered in the preprocedure room, in the absence of the endoscopist or the research assistant. 5 minute before the UGE without any sedation
Study: NCT05435274
Drug: HS-10376
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-10376 will be administered orally once daily in a continuous regimen
Study: NCT05883085
Drug: Anlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive anlotinib hydrochloride 8-12mg orally once daily on days 1-14. Courses repeat every 21 days
Study: NCT05753150
Drug: Tafenoquine
Normalized name: tafenoquine
DrugBank: Tafenoquine (DB06608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tafenoquine 300 mg (2x150 mg tablets)
Study: NCT05753150
Drug: Primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily primaquine adjusted by weight (0.25 mg/kg/day for 14 days)
Study: NCT05753150
Drug: Primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly primaquine adjusted by weight (0.75mg/kg/week for 8 weeks)
Study: NCT05851014
Drug: GB491 combined with Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients were randomized to receive GB491 150 mg orally twice daily, depending on their assignment. Letrozole 2.5 mg orally once a day from the first day of cycle 1 (one cycle every 28 days)
Study: NCT05851014
Drug: Placebo combined with Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients were randomized to receive placebo orally twice daily, depending on their assignment. Letrozole 2.5 mg orally once a day from the first day of cycle 1 (one cycle every 28 days)
Study: NCT05278676
Drug: Dotinurad
Normalized name: Dotinurad
DrugBank: Dotinurad (DB16145)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Dotinurad oral tablet.
Study: NCT04603508
Drug: EMPAGLIFLOZIN
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 25 mg coated tablet.
Study: NCT05629468
Drug: Benzoyl Peroxide 4 % Topical Cream
Normalized name: benzoyl peroxide 4 % Topical Cream
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical cream
Study: NCT00532506
Drug: SK-0403
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04705051
Drug: Venglustat GZ402671
Normalized name: Venglustat
DrugBank: Venglustat (DB14966)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule Route of administration: oral
Study: NCT06422429
Drug: PI Youtiao
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45g 4 times a week for 4 months
Study: NCT05320380
Drug: Anti-CD123 ADC IMGN632
Normalized name: anti-CD11a
DrugBank: IMGN632 (DB17337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05320380
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT and IV
Study: NCT05320380
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05320380
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
Normalized name: DAUNORUBICIN/CYTARABINE
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05816070
Drug: Ofloxacin Eye Drops
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Four times per day for day 1-2 and three times per day for day 3-7
Study: NCT04868747
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The participants receive perioperative lidocaine infusion with general anesthesia for gastrectomy.
Study: NCT00006200
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006200
Drug: dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06576271
Drug: Belimumab
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Belimumab will be administered to participants.
Study: NCT06057610
Drug: SHR-A1811 Injection
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-A1811 Injection
Study: NCT06057610
Drug: SHR-A1811 Injection ； Pertuzumab Injection
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SHR-A1811 Injection ； Pertuzumab Injection
Study: NCT06057610
Drug: Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection
Study: NCT05756972
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT05756972
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV infusion
Study: NCT04645823
Drug: Lidocaine 1% Injectable Solution
Normalized name: lidocaine 1% injectable solution
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fentanyl citrate 100µg and lidocaine hydrochloride 80 mg in 10 ml volume
Study: NCT05690698
Drug: Haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antipsychotic
Study: NCT03123965
Drug: glecaprevir
Normalized name: Glecaprevir
DrugBank: Glecaprevir (DB13879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glecaprevir will be administered orally.
Study: NCT03123965
Drug: pibrentasvir
Normalized name: Pibrentasvir
DrugBank: Pibrentasvir (DB13878)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pibrentasvir will be administered orally.
Study: NCT05552859
Drug: Insulin glargine 300 U/mL
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 300 U/mL in the SoloStar pen, self-administered once daily for 24 weeks.
Study: NCT05552859
Drug: Insulin degludec 100 U/mL
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec 100 U/mL will be self- administered once daily for 24 weeks.
Study: NCT06213610
Drug: Perindopril tablet
Normalized name: perindopril Oral Tablet
DrugBank: Perindopril (DB00790)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perindopril is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 8 mg of perindopril tert-butylamine.
Study: NCT05579119
Drug: Sitagliptin 100mg
Normalized name: Sitagliptin 100mg Oral tablet
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin 100 mg po once daily.
Study: NCT05579119
Drug: Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glargine once daily.
Study: NCT05579119
Drug: Lispro
Normalized name: Lispro PRC
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Correctional doses of lispro if needed for elevated blood glucose using sliding scale insulin (SSI).
Study: NCT05651841
Drug: Tezepelumab
Normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tezepelumab is supplied as a sterile, single-use, preservation-free, clear, colourless to slightly yellow liquid for subcutaneous administration in accessorized pre-filled syringes (APFS).~Injections will be performed by study staff (doctors or nurses) during face-to-face study visits in participating centres.~Subcutaneous injections are performed in a different body-part following the suggested rotation diagram.
Study: NCT05608070
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin 30 IU in 500 ml IV at a rate of 5 IU/h (83.33 ml/h). The infusion will be started intra-operative once the uterus is removed and will continue to run until completion of the medication or discharge from PACU criteria are met, whichever occurs first.
Study: NCT06402968
Drug: Clevidipine Injection
Normalized name: clevidipine Injection
DrugBank: Clevidipine (DB04920)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sites will be trained and instructed to administer IV clevidipine according to Food and Drug Administration label, which recommends starting at 1-2 mg/hour, and then doubling the dose initially at short (90 second) intervals. As the BP approaches the goal, the increase in doses should be less than doubling and the time between dose adjustments should be lengthened to every 5-10 minutes. The desired therapeutic response for most patients occurs at doses of 4-6 mg/hour. Most patients have been treated with maximum doses of 16 mg/hour or less. There is limited short-term experience with doses up to 32 mg/hour, and because of lipid load restrictions, no more than 1000 mL or an average of 21 mg/hour of Clevidipine infusion is recommended per 24-hour period. There is little experience beyond 72 hours at any dose.
Study: NCT06344390
Drug: Pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take pentoxifylline 0.4 g twice daily
Study: NCT06495931
Drug: HRS-1780 tablets
Normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-1780 tablets, three times
Study: NCT06495931
Drug: HRS-7535 tablets
Normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-7535 tablets ，three times or nine times
Study: NCT05838209
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: saline solution 0.09% used as an adjunctive as scaling and root planing
Study: NCT04945213
Drug: Biperiden
Normalized name: Biperiden
DrugBank: Biperiden (DB00810)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg of biperiden diluted in 100 ml of 0.9% saline - every 6 hours for 10 consecutive days - IV
Study: NCT05200429
Drug: Trikafta
Normalized name: Trikafta
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Highly Effective CFTR Modulator Therapy
Study: NCT05563571
Drug: Methylprednisolon, Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-articular cortisone injection
Study: NCT05491447
Drug: BMX-010
Normalized name: BMX-001 free base
DrugBank: BMX-001 free base (DB17516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment
Study: NCT06169995
Drug: Remimazolam Tosilate
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bolus dose: 5mg，IV supplemental dose: 2.5mg，IV
Study: NCT05982834
Drug: Disitamab Vedotin combined with fruquintinib and Tislelizumab
Normalized name: Tislelizumab
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disitamab Vedotin 2.5mg/m2 ivgtt d1,15, fruquintinib 4mg qd po d1-21 and Tislelizumab 300mg ivgtt,q4w
Study: NCT06423872
Drug: ZT002
Normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a single subcutaneous (SC) ZT002 injection.
Study: NCT05316259
Drug: BPI-16350
Normalized name: BPI-3016
DrugBank: BPI-3016 (DB15158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05023278
Drug: Venlafaxine 37.5 MG
Normalized name: venlafaxine 37.5 MG
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: venlafaxine 37.5mg daily for 7 consecutive days.
Study: NCT00002268
Drug: Sevirumab
Normalized name: Sevirumab
DrugBank: Sevirumab (DB17771)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05518799
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive 2 mg midazolam orally on day 1 of the study and 1 mg midazolam intravenously on day 2 of the study.